{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:18:25Z","timestamp":1760523505428},"publisher-location":"Cham","reference-count":61,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030105068"},{"type":"electronic","value":"9783030105075"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1007\/164_2017_21","type":"book-chapter","created":{"date-parts":[[2017,3,28]],"date-time":"2017-03-28T16:21:12Z","timestamp":1490718072000},"page":"181-194","source":"Crossref","is-referenced-by-count":9,"title":["Resistance to Hormonal Therapy in Prostate Cancer"],"prefix":"10.1007","author":[{"given":"Alfredo","family":"Berruti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Dalla Volta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"issue":"11","key":"21_CR1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H et al (2014) Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11):1028\u20131038","journal-title":"N Engl J Med"},{"issue":"5","key":"21_CR2","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","volume":"1","author":"ES Antonarakis","year":"2015","unstructured":"Antonarakis ES, Lu C, Luber B et al (2015) Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol 1(5):582\u2013591","journal-title":"JAMA Oncol"},{"issue":"6","key":"21_CR3","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","volume":"155","author":"VK Arora","year":"2013","unstructured":"Arora VK, Schenkein E, Murali R et al (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309\u20131322","journal-title":"Cell"},{"issue":"10","key":"21_CR4","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","volume":"21","author":"AA Azad","year":"2015","unstructured":"Azad AA, Volik SV, Wyatt AW et al (2015) Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res 21(10):2315\u20132324","journal-title":"Clin Cancer Res"},{"issue":"3","key":"21_CR5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22(3):298\u2013305","journal-title":"Nat Med"},{"issue":"3","key":"21_CR6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clgc.2013.01.002","volume":"11","author":"V Bertaglia","year":"2013","unstructured":"Bertaglia V, Tucci M, Fiori C et al (2013) Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 11(3):325\u2013330.e1","journal-title":"Clin Genitourin Cancer"},{"issue":"254","key":"21_CR7","doi-asserted-by":"crossref","first-page":"254ra125","DOI":"10.1126\/scitranslmed.3009448","volume":"6","author":"S Carreira","year":"2014","unstructured":"Carreira S, Romanel A, Goodall J et al (2014) Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 6(254):254ra125","journal-title":"Sci Transl Med"},{"issue":"2","key":"21_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18632\/oncotarget.1296","volume":"5","author":"YT Chiang","year":"2014","unstructured":"Chiang YT, Wang K, Fazli L et al (2014) Gata2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 5(2):451\u2013461","journal-title":"Oncotarget"},{"issue":"11","key":"21_CR9","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1210\/en.2014-1337","volume":"155","author":"E Cho","year":"2014","unstructured":"Cho E, Montgomery RB, Mostaghel EA (2014) Minireview: Slco and abc transporters: a role for steroid transport in prostate cancer progression. Endocrinology 155(11):4124\u20134132","journal-title":"Endocrinology"},{"issue":"4","key":"21_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvi\u00e8re O, Wiegel T, Mottet N (2017) Eau-estro-siog guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630\u2013642. doi: 10.1016\/j.eururo.2016.08.002","journal-title":"Eur Urol"},{"issue":"1","key":"21_CR11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/0008-5472.CAN-16-1656","volume":"77","author":"KC Day","year":"2017","unstructured":"Day KC, Hiles GL, Kozminsky M et al (2017) Her2 and egfr overexpression support metastatic progression of prostate cancer to bone. Cancer Res 77(1):74\u201385","journal-title":"Cancer Res"},{"issue":"20","key":"21_CR12","first-page":"5632","volume":"62","author":"JD Debes","year":"2002","unstructured":"Debes JD, Schmidt LJ, Huang H, Tindall DJ (2002) P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62(20):5632\u20135636","journal-title":"Cancer Res"},{"issue":"13","key":"21_CR13","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68(13):5469\u20135477","journal-title":"Cancer Res"},{"issue":"12","key":"21_CR14","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1210\/me.2005-0231","volume":"19","author":"J Duff","year":"2005","unstructured":"Duff J, Mcewan IJ (2005) Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions. Mol Endocrinol 19(12):2943\u20132954","journal-title":"Mol Endocrinol"},{"issue":"1","key":"21_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","volume":"67","author":"E Efstathiou","year":"2015","unstructured":"Efstathiou E, Titus M, Wen S et al (2015) Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol 67(1):53\u201360","journal-title":"Eur Urol"},{"issue":"6","key":"21_CR16","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/humu.20044","volume":"23","author":"B Gottlieb","year":"2004","unstructured":"Gottlieb B, Beitel LK, Wu JH, Trifiro M (2004) The androgen receptor gene mutations database (ardb): 2004 update. Hum Mutat 23(6):527\u2013533","journal-title":"Hum Mutat"},{"issue":"7406","key":"21_CR17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","volume":"487","author":"CS Grasso","year":"2012","unstructured":"Grasso CS, Wu YM, Robinson DR et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406):239\u2013243","journal-title":"Nature"},{"issue":"2","key":"21_CR18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116691","volume":"10","author":"T Grindstad","year":"2015","unstructured":"Grindstad T, Andersen S, Al-Saad S et al (2015) High progesterone receptor expression in prostate cancer is associated with clinical failure. PLoS One 10(2):e0116691","journal-title":"PLoS One"},{"issue":"10","key":"21_CR19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1470-2045(16)30227-3","volume":"17","author":"JW Hearn","year":"2016","unstructured":"Hearn JW, Abuali G, Reichard CA et al (2016) Hsd3b1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17(10):1435\u20131444","journal-title":"Lancet Oncol"},{"issue":"4","key":"21_CR20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019059","volume":"6","author":"E Hornberg","year":"2011","unstructured":"Hornberg E, Ylitalo EB, Crnalic S et al (2011) Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One 6(4):e19059","journal-title":"PLoS One"},{"issue":"1","key":"21_CR21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu R, Dunn TA, Wei S et al (2009) Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 69(1):16\u201322","journal-title":"Cancer Res"},{"issue":"15","key":"21_CR22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/pros.21382","volume":"71","author":"R Hu","year":"2011","unstructured":"Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71(15):1656\u20131667","journal-title":"Prostate"},{"issue":"9","key":"21_CR23","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","volume":"3","author":"JD Joseph","year":"2013","unstructured":"Joseph JD, Lu N, Qian J et al (2013) A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and arn-509. Cancer Discov 3(9):1020\u20131029","journal-title":"Cancer Discov"},{"issue":"3","key":"21_CR24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.eururo.2014.09.049","volume":"67","author":"T Karantanos","year":"2015","unstructured":"Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB (2015) Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67(3):470\u2013479","journal-title":"Eur Urol"},{"issue":"1","key":"21_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2013.08.015","volume":"65","author":"M Khera","year":"2014","unstructured":"Khera M, Crawford D, Morales A, Salonia A, Morgentaler A (2014) A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 65(1):115\u2013123","journal-title":"Eur Urol"},{"issue":"2","key":"21_CR26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pros.10139","volume":"53","author":"E Koh","year":"2002","unstructured":"Koh E, Noda T, Kanaya J, Namiki M (2002) Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53(2):154\u2013159","journal-title":"Prostate"},{"issue":"9","key":"21_CR27","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/2159-8290.CD-13-0142","volume":"3","author":"M Korpal","year":"2013","unstructured":"Korpal M, Korn JM, Gao X et al (2013) An f876l mutation in androgen receptor confers genetic and phenotypic resistance to mdv3100 (enzalutamide). Cancer Discov 3(9):1030\u20131043","journal-title":"Cancer Discov"},{"issue":"2","key":"21_CR28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrurol.2010.231","volume":"8","author":"F Labrie","year":"2011","unstructured":"Labrie F (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8(2):73\u201385","journal-title":"Nat Rev Urol"},{"issue":"39","key":"21_CR29","doi-asserted-by":"crossref","first-page":"15710","DOI":"10.1073\/pnas.1218168110","volume":"110","author":"E Lee","year":"2013","unstructured":"Lee E, Madar A, David G, Garabedian MJ, Dasgupta R, Logan SK (2013) Inhibition of androgen receptor and beta-catenin activity in prostate cancer. Proc Natl Acad Sci U S A 110(39):15710\u201315715","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7560","key":"21_CR30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","volume":"523","author":"Z Li","year":"2015","unstructured":"Li Z, Bishop AC, Alyamani M et al (2015) Conversion of abiraterone to d4a drives anti-tumour activity in prostate cancer. Nature 523(7560):347\u2013351","journal-title":"Nature"},{"issue":"12","key":"21_CR31","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1039\/C5MB00499C","volume":"11","author":"H Liu","year":"2015","unstructured":"Liu H, An X, Li S, Wang Y, Li J, Liu H (2015) Interaction mechanism exploration of r-bicalutamide\/s-1 with wt\/w741l ar using molecular dynamics simulations. Mol BioSyst 11(12):3347\u20133354","journal-title":"Mol BioSyst"},{"issue":"12","key":"21_CR32","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","volume":"25","author":"DA Loblaw","year":"2007","unstructured":"Loblaw DA, Virgo KS, Nam R et al (2007) Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an american society of clinical oncology practice guideline. J Clin Oncol 25(12):1596\u20131605","journal-title":"J Clin Oncol"},{"issue":"4","key":"21_CR33","first-page":"944","volume":"60","author":"M Marcelli","year":"2000","unstructured":"Marcelli M, Ittmann M, Mariani S et al (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60(4):944\u2013949","journal-title":"Cancer Res"},{"issue":"18","key":"21_CR34","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S et al (2015) DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373(18):1697\u20131708","journal-title":"N Engl J Med"},{"issue":"3","key":"21_CR35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.eururo.2016.08.037","volume":"71","author":"J Mateo","year":"2017","unstructured":"Mateo J, Boysen G, Barbieri CE et al (2017) DNA repair in prostate cancer: biology and clinical implications. Eur Urol 71(3):417\u2013425","journal-title":"Eur Urol"},{"issue":"11","key":"21_CR36","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery RB, Mostaghel EA, Vessella R et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68(11):4447\u20134454","journal-title":"Cancer Res"},{"key":"21_CR37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/CMAR.S39318","volume":"6","author":"EA Mostaghel","year":"2014","unstructured":"Mostaghel EA (2014) Abiraterone in the treatment of metastatic castration-resistant prostate cancer. Cancer Manag Res 6:39\u201351","journal-title":"Cancer Manag Res"},{"issue":"21","key":"21_CR38","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","volume":"10","author":"T Nishiyama","year":"2004","unstructured":"Nishiyama T, Hashimoto Y, Takahashi K (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10(21):7121\u20137126","journal-title":"Clin Cancer Res"},{"key":"21_CR39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2015.05.010","volume":"153","author":"TM Penning","year":"2015","unstructured":"Penning TM (2015) Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (crpc). J Steroid Biochem Mol Biol 153:105\u2013113","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"21_CR40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM et al (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161(5):1215\u20131228","journal-title":"Cell"},{"issue":"22","key":"21_CR41","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","volume":"31","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Molina A, Li J et al (2013) Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase iii trial. J Clin Oncol 31(22):2791\u20132798","journal-title":"J Clin Oncol"},{"issue":"2","key":"21_CR42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bju.13123","volume":"117","author":"J Schalken","year":"2016","unstructured":"Schalken J, Fitzpatrick JM (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int 117(2):215\u2013225","journal-title":"BJU Int"},{"issue":"11","key":"21_CR43","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","volume":"2","author":"HI Scher","year":"2016","unstructured":"Scher HI, Lu D, Schreiber NA et al (2016) Association of ar-v7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol 2(11):1441\u20131449","journal-title":"JAMA Oncol"},{"key":"21_CR44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2121-9-4","volume":"9","author":"L Schweizer","year":"2008","unstructured":"Schweizer L, Rizzo CA, Spires TE et al (2008) The androgen receptor can signal through wnt\/beta-catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol 9:4","journal-title":"BMC Cell Biol"},{"key":"21_CR45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3925","author":"J Steinestel","year":"2015","unstructured":"Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ, Steinestel J, Luedeke M, Arndt A, Schnoeller TJ, Lennerz JK, Wurm C, Maier C, Cronauer MV, Steinestel K, Schrader AJ (2015) Detecting predictive androgen receptor modifications in circulating prostate cancer cells. Oncotarget. doi: 10.18632\/oncotarget.3925","journal-title":"Oncotarget"},{"issue":"3","key":"21_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/ijc.10495","volume":"100","author":"K Steketee","year":"2002","unstructured":"Steketee K, Timmerman L, Ziel-Van Der Made AC, Doesburg P, Brinkmann AO, Trapman J (2002) Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of h874 and mutation hot spot t877 in prostate cancer. Int J Cancer 100(3):309\u2013317","journal-title":"Int J Cancer"},{"issue":"8","key":"21_CR47","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","volume":"120","author":"S Sun","year":"2010","unstructured":"Sun S, Sprenger CC, Vessella RL et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120(8):2715\u20132730","journal-title":"J Clin Invest"},{"issue":"11","key":"21_CR48","first-page":"2511","volume":"59","author":"ME Taplin","year":"1999","unstructured":"Taplin ME, Bubley GJ, Ko YJ et al (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59(11):2511\u20132515","journal-title":"Cancer Res"},{"issue":"33","key":"21_CR49","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","volume":"32","author":"ME Taplin","year":"2014","unstructured":"Taplin ME, Montgomery B, Logothetis CJ et al (2014) Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase ii neoadjuvant study. J Clin Oncol 32(33):3705\u20133715","journal-title":"J Clin Oncol"},{"issue":"1","key":"21_CR50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","volume":"18","author":"BS Taylor","year":"2010","unstructured":"Taylor BS, Schultz N, Hieronymus H et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1):11\u201322","journal-title":"Cancer Cell"},{"key":"21_CR51","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fonc.2014.00060","volume":"4","author":"S Terry","year":"2014","unstructured":"Terry S, Beltran H (2014) The many faces of neuroendocrine differentiation in prostate cancer progression. Front Oncol 4:60","journal-title":"Front Oncol"},{"issue":"8","key":"21_CR52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/pros.20542","volume":"67","author":"M Urushibara","year":"2007","unstructured":"Urushibara M, Ishioka J, Hyochi N et al (2007) Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate 67(8):799\u2013807","journal-title":"Prostate"},{"issue":"8","key":"21_CR53","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/bi00123a026","volume":"31","author":"J Veldscholte","year":"1992","unstructured":"Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (1992) Anti-androgens and the mutated androgen receptor of lncap cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31(8):2393\u20132399","journal-title":"Biochemistry"},{"issue":"4","key":"21_CR54","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1464-410X.2007.07261.x","volume":"101","author":"R Venkitaraman","year":"2008","unstructured":"Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101(4):440\u2013443","journal-title":"BJU Int"},{"issue":"3","key":"21_CR55","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-11-2521","volume":"18","author":"X Wan","year":"2012","unstructured":"Wan X, Liu J, Lu JF et al (2012) Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 18(3):726\u2013736","journal-title":"Clin Cancer Res"},{"issue":"23","key":"21_CR56","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1158\/0008-5472.CAN-08-1718","volume":"68","author":"G Wang","year":"2008","unstructured":"Wang G, Wang J, Sadar MD (2008) Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 68(23):9918\u20139927","journal-title":"Cancer Res"},{"issue":"30","key":"21_CR57","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang HT, Yao YH, Li BG, Tang Y, Chang JW, Zhang J (2014) Neuroendocrine prostate cancer (nepc) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of nepc and survival from nepc diagnosis-a systematic review and pooled analysis. J Clin Oncol 32(30):3383\u20133390","journal-title":"J Clin Oncol"},{"issue":"39","key":"21_CR58","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","volume":"107","author":"PA Watson","year":"2010","unstructured":"Watson PA, Chen YF, Balbas MD et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107(39):16759\u201316765","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"21_CR59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"21_CR60","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1200\/JCO.2010.31.2405","volume":"29","author":"M Yang","year":"2011","unstructured":"Yang M, Xie W, Mostaghel E et al (2011) Slco2b1 and slco1b3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 29(18):2565\u20132573","journal-title":"J Clin Oncol"},{"issue":"33","key":"21_CR61","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1038\/onc.2015.496","volume":"35","author":"JC Zhao","year":"2016","unstructured":"Zhao JC, Fong KW, Jin HJ, Yang YA, Kim J, Yu J (2016) Foxa1 acts upstream of gata2 and ar in hormonal regulation of gene expression. Oncogene 35(33):4335\u20134344","journal-title":"Oncogene"}],"container-title":["Handbook of Experimental Pharmacology","Mechanisms of Drug Resistance in Cancer Therapy"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2017_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T09:01:56Z","timestamp":1719133316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2017_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9783030105068","9783030105075"],"references-count":61,"URL":"https:\/\/doi.org\/10.1007\/164_2017_21","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"type":"print","value":"0171-2004"},{"type":"electronic","value":"1865-0325"}],"subject":[],"published":{"date-parts":[[2017]]}}}